REGENXBIO Inc.
RGNX
Positions held
Your positionsRGNX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $534.05M | Enterprise value | $678.99M | Trailing P/E | — | Forward P/E | -2.72 |
| PEG | — | Price / book | 6.11 | Beta | 1.13 | Dividend yield | 0.00% |
| Revenue growth | 4.1% | Earnings growth | — | Gross margin | -44.9% | Operating margin | 27.1% |
| Profit margin | -112.6% | ROE | -137.6% | ROA | -21.2% | Debt / equity | 3.49 |
| Current ratio | 2.86 | Free cash flow | -$184.26M | Analyst recommendation | buy | Mean target | $23.58 |
| 52w high | $16.19 | 52w low | $5.46 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $108M | $6.4M | $30.3M | $29.7M | $21.4M | — |
| Op margin | 27.1% | -1304.0% | -190.0% | -176.3% | -296.3% | — |
| Net income | $22.7M | -$90.1M | -$67.1M | -$61.9M | -$70.9M | — |
| Gross margin | 99.0% | -73.2% | 80.5% | 80.7% | 75.6% | — |
| Gross profit | $107M | -$4.7M | $24.4M | $24.0M | $16.1M | — |
| Operating income | $29.3M | -$83.4M | -$57.6M | -$52.4M | -$63.3M | — |
- Revenue +1590% vs prior quarter ($108M vs $6.4M).
- Gross margin 99% (was -73.2% prior quarter).
- Operating margin expanded to 27.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $170M | $83.3M | $90.2M | $113M | — |
| Op margin | -94.6% | -277.5% | -297.1% | -233.2% | — |
| Net income | -$194M | -$227M | -$263M | -$280M | — |
| Gross margin | 88.1% | 59.7% | 58.8% | 51.6% | — |
| Gross profit | $150M | $49.8M | $53.0M | $58.2M | — |
| Operating income | -$161M | -$231M | -$268M | -$263M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Microsoft upgraded, HubSpot downgraded: Wall Street's top analyst calls
2026-10-05 · Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
2026-10-05 · Mizuho Initiates REGENXBIO at Outperform With $22 Price Target
2026-09-25 · Regenxbio stock gains on positive gene therapy trial data
2026-09-16 · Trump Administration Shift Puts This Corner of Biotech Back in Favor
2026-09-08 · REGENXBIO to Participate in Upcoming Investor Conferences
2026-09-05 · Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
2026-08-28 · Top Premarket Gainers
2026-08-25 · RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
2026-08-25 · REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
2026-08-25 · Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
Price (daily)
Full chart · RSI · MACD · patterns